Background: Pivotal studies on drug-eluting stents have excluded hemodialysis (HD) patients. No quantitative coronary angiography (QCA) analysis has been reported.
oronary artery disease has different characteristics in hemodialysis (HD) patients as compared to patients with normal renal function. Dialysis patients have extremely poor prognosis, with adjusted all-cause mortality rates 6.7-to 8.5-fold higher than those of their non-dialysis counterparts in the general population. 1 The cardiovascular mortality rate of dialysis patients is 3-to 6-fold higher than that from infection. 1 Despite clear evidence of statins preventing coronary events in patients with normal renal function, the randomized controlled trial in dialysis patients (4D) found no evidence of benefit from statins. 2 Coronary artery calcification is frequent and severe in HD patients. 3 All the well-designed studies on drug-eluting stents (DES) have excluded HD patients probably to avoid heterogeneity in the treated group. These studies have proven that DES is associated with lower event rates than bare metal stents (BMS) in patients with normal renal function. Thus, available data of DES in HD patients are from single-center retrospective studies. They reported that C 1857 OUCH: SES for HD Patients sirolimus-eluting stent (SES) implantation was associated with lower TLR rates than BMS implantation. 4-7 However, several reports showed completely opposite results, with SES failing to reduce rates of any events such as TLR, mortality, or major adverse cardiac events compared with BMS. 8-11 Furthermore, to our knowledge, no quantitative coronary angiography (QCA) analysis has been reported for DES in HD patients. In view of the uncertain value of DES in HD patients to date, we conducted this prospective non-randomized multicenter trial of SES implantation using QCA carried out in an independent core laboratory.
Methods

Study Design and Patient Population
The OUCH Study (OUtcome of Cypher stent in Hemodialysis) is a prospective multicenter registry study targeting the outcome of sirolimus-eluting coronary stent implantation in patients undergoing maintenance HD. Inclusion criteria were end-stage renal disease requiring HD, age ≥21 years, and elective percutaneous coronary intervention (PCI) with SES. Exclusion criteria were a history of surviving an episode of sudden death, cardiogenic shock, emergency PCI, ST-segment elevation myocardial infarction (MI), intolerance to antiplatelet drugs, coronary stenting within 6 months, in-stent resteno-sis following DES implantation, MI within 30 days, severe valvular heart disease, critical limb ischemia, patients waiting for renal transplantation, and total occlusion of the target vessel. All patients received information about the inclusion and exclusion criteria for the study, and gave written informed consent.
All PCI procedures were carried out at the discretion of the operator and with the objective of achieving optimal results, although in elective situations the use of SES (Cypher Bx Velocity) was mandatory. BMS could be used only to facilitate bail-out in cases where SES caused edge dissection. Use of other DES was prohibited; however, rotablator could be used when necessary. Use of intravascular ultrasound (IVUS) to confirm optimal stent expansion was encouraged.
Follow-up was started from the date of the PCI. Planned staged PCI procedures were not considered as adverse events. The "target lesion" was defined at the time of the initial PCI. Follow-up clinical data were collected at 1, 8, and 12 months, and follow-up coronary angiography was performed in 83% of patients at 8 months. All patients received antiplatelet agents, both aspirin 80-200 mg/day and a thienopyridine derivative (clopidogrel 75 mg or ticlopidine 200 mg daily). Maintenance HD was performed 3 times a week using a high performance membrane. BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, lowdensity lipoprotein cholesterol; CAD, coronary artery disease; DM, diabetes mellitus; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft surgery; ACEI, angiotensin-converting-enzyme inhibitor; ARB, angiotensin receptor blocker. IKARI Y et al.
Data Management and Definitions
Data were collected and submitted from the participating sites using case record forms and study codes to protect subject identity. A private independent contract research organization, Japan Cardiocore (Tokyo, Japan), was retained to serve as the administrator of the study.
In the presence of Thrombosis In Myocardial Infarction (TIMI) grade 3 flow, angiographic success was defined as the achievement of a minimum stenosis diameter reduction to <50%. Overall procedural success was defined as presence of angiographic success plus absence of a major complication, and procedural failure as either lack of angiographic success or occurrence of a major complication.
All the angiographic data were transmitted to the independent core laboratory (Japan Cardiocore) and assessed by experts blinded to patient data. QCA was carried out in the core laboratory using CAAS 5.4 (Pie Medical Imaging, Maastricht, The Netherlands).
The primary endpoint of the study was occurrence of targetvessel failure (TVF), defined as cardiac death, MI in the target vessel, and the requirement for target-vessel revascularization (TVR) within the first year after PCI. Major adverse cardiac event was defined as death, MI, repeat PCI, or coronary artery bypass graft surgery. Deaths were classified as cardiac or noncardiac. Sudden death as a result of an unknown cause was classified as a cardiac death. Repeat PCI was categorized as target lesion, target vessel, or non-TVR according to whether the index lesion or artery was involved. Stent thrombosis was categorized as definite, probable, or possible according to the ARC definition. 12
Statistical Analysis
The primary endpoint was TVF at 12 months. In previous reports, HD patients had a 52% mortality rate at 2.3 years of follow-up, 13 and 0.4 acute MI per person-year. 14 Patients in this study were supposed to have worse prognosis than normal HD patients because of the co-existence of coronary artery disease. In non-dialysis patients, the TVF of SES at 1 year was reported as approximately 10%. 15-18 Because of the much higher incidence of complications in HD patients, the target case number for this registry was set at 120 for 12 months of follow-up, which was deemed sufficient to make valid observations on the primary endpoint.
Continuous variables were expressed as mean ± SD and were compared with the Student's unpaired t test. Categorical variables were expressed as counts and percentages, and the chisquared test was used for comparison. Cumulative 1-year adverse event rates were estimated according to the Kaplan-Meier method and compared by the log-rank test. Stepwise logistic analysis was performed to detect predictors of groups. All analyses were performed with the SAS 9.2 system. This trial is registered with UMIN as number UMIN 000001155.
Results
Baseline and Procedural Characteristics
A total of 120 patients who fulfilled the inclusion criteria were enrolled between June 2007 and May 2009. After an initial successful PCI, consent was withdrawn by 3 patients, and thus 117 individuals completed the study. A total of 139 target lesions were present in these 117 patients. Clinical follow-up was available in 100% of patients at 12 months and angio- Overall, the mean age of patients was 65 years; 69% were male, 91% had hypertension; and 70% had diabetes ( Table 1) . The average duration of HD was 5.8 years. Multivessel disease was present in 38%; and non-protected left main disease in 8%. The mean ejection fraction was 57%; and 21% of patients had an ejection fraction <50%. Baseline blood tests showed a mean B-type natriuretic peptide concentration of 654 pg/ml (normal <18.4 pg/ml) and troponin I level of 0.21 ng/ml (normal <0.04 ng/ml).
Lesion characteristics and coronary intervention procedures are shown in Table 2 . American Heart Association (AHA)/ ACC type B2/C lesions were present in 82.7%, and angiographically severe calcification was found in 33.8%. Rotational atherectomy was employed in 28% of patients, and bi- furcation lesions were present in 42 (30.2%). To treat these lesions, 1 stent was used in 37 patients, whereas 2 stents were used in 6 patients (2 Culotte, 2 crush, and 2 T stents).
QCA Data
Data from QCA performed in an independent core laboratory are shown in Table 3 . Average in-stent late loss was 0.69± 0.93 mm. The histogram of in-stent late loss is shown in Figure. A total of 76% of lesions were located less than 1 mm. Distri-bution of these lesions is similar to the reported pattern following SES implantation in normal renal function (Figure S1,S2) . Twenty-four percent of lesions were outliers located more than 1 mm.
Clinical Follow-up Data
The mortality rate at 1 year was 9.4%, with 2.6% cardiac and 6.8% non-cardiac deaths ( Table 4 ). MI was observed in 1.4% of patients, and repeat revascularization was carried out in 31.2% (28.2% PCI and 5.1% coronary artery bypass graft) including 22.2% with TLR, 1.7% with non-target lesion TVR, and 7.5% with non-TVR. Definite/probable stent thrombosis was present in 0.9% of patients according to the ARC definition. Admission as a result of heart failure was seen in 6.8%. TVF, the primary endpoint, was present in 24.9% of patients. Predictive factors of TVF were analyzed in Table 5 . Severe coronary calcification and use of rotational atherectomy had a high TVF rate. Patients with TVF were younger and had lower low-density lipoprotein (LDL) cholesterol level. Diabetes, AHA/ACC type B2/C lesion, or stent length did not show significant correlation with TVF.
Factors Relating to the Bimodal In-Stent Late Loss Distribution
Using 1 mm as the cut-off value of late lumen loss based on the previous reports about late loss histogram, 16,19-21 we divided the 113 lesions into Group 1 (normal distribution, n=86) and Group 2 (outliers, n=27). The average late loss in Group 
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1 was 0.20±0.29 mm and that in Group 2 was 2.07±0.62 mm. Factors that are relevant to the in-stent late loss distribution are shown in Table 6 . Group 2 were younger but had longer duration of HD, lower total cholesterol level, and more severe angiographic calcification. Due to severe calcification, frequent rotational atherectomy and difficulty with IVUS catheter passage were observed. Interestingly, the following factors did not show significant difference: frequency of AHA/ACC type C lesions, diabetic nephropathy, multivessel disease, or baseline phosphate level.
Multivariate stepwise logistic regression analysis identified angiographic calcification as the exclusive factor that distinguished Group 1 from Group 2 ( Table 7) .
Discussion
In the OUCH Study, TVF 1 year following SES implantation was 24.9%, and average in-stent late loss at 8 months was 0.69±0.93 mm in patients undergoing maintenance HD. To our knowledge this is the first prospective report of TVF and in-stent late loss following DES implantation in HD patients. In previous reports, TVF 1 year following SES implantation in normal renal function was 9.8% in SIRIUS, 15 11 .5% in ENDEAVOR III, 16 10.9% in ASCOT/TOSCA-4, 17 and 9.3% in J-PMS studies, 18 indicating that TVF following SES implantation was in the 10% range. Accordingly, the figure of 24.9% for TVF in the OUCH Study clearly shows that HD patients had greater risk than that of patients with normal renal function. The high TVF rate supports the results of previous large registry studies showing that HD was a predictor of death, MI, 18 the requirement for TLR, 22-25 late stent thrombosis, 26 and other major adverse cardiac events 27,28 following SES implantation.
Predictors of TVF in HD patients were clearly different from these with normal renal function as shown in Table 5 . Risk factors such as diabetes, stent length, or AHA/ACC type B2/C lesions did not show significant correlation with TVF. However, coronary calcification and use of rotational atherectomy as a result of calcification were predictors of TVF. Interestingly, patients with TVF were younger and had lower LDL cholesterol level. These observations are novel and might be specific in HD patients. Mean in-stent late loss following SES implantation in normal renal function was 0.01 mm in RAVEL, 29 0.17 mm in SIR-IUS, 30 0.12 mm in C-SIRIUS, 31 and 0.20 mm in E-SIRIUS, 32 further validating the striking difference with that in HD patients (0.69±0.93 mm). Histograms of late loss after SES implantation reported by Cosgrave et al, 19 Sabate et al, 20 Kandzari et al, 16 and Mauri et al 21 showed a clear normal distribution (Figure S1) . One can speculate late loss distribution is different in HD patients because of the worse clinical outcome. [33] [34] [35] Although late loss should be distributed evenly normally in HD patients, there were several hypotheses to explain it: (1) higher average with the same deviation; (2) the same average with the wider deviation; (3) both higher and wide deviation; and (4) existence of outliers with the same average and the same deviation. The present study showed that the answer is the latter: the existence of many outliers with the same average and the same deviation (Figure S2) . The group of 76% These data suggest that there are 2 groups of HD patients. In 1 group, SES appears to limit intimal hyperplasia in a manner similar to that in the setting of normal renal function. In the other group, this beneficial effect is lacking. Coronary calcification was the strong predictor for the outliers. Also these patients were younger with longer duration of HD and lower cholesterol level. The variable results of SES in previous studies for HD patients might be a direct result of the selection bias from the significant number of outliers. This result raises important questions; 1) what is the underlying mechanism underlying lack or minimized of sirolimus effects in a significant number of HD patients? and 2) is it possible to determine the response against sirolimus before SES implantation? Further studies are necessary to clarify these HD specific problems on DES.
There are several limitations in this study. This was a prospective but non-randomized study. The case number was limited to 117. However, previous studies reporting the outcomes of SES implantation in treating HD patients have included fewer than 100 cases, 4-10,36 and the meta-analysis mentioned above included only 279 DES cases from 5 studies. 37 The current study might be one of the largest prospective studies thus far reported that targets HD patients receiving SES treatment. Furthermore, this is also the first report of QCA using DES in HD patients.
In conclusion, the TVF rate of 24.9% following SES implantation in HD patients was higher than that in the setting of normal renal function with a TVF rate of approximately 10%. [15] [16] [17] [18] The interesting distribution of late loss in HD patients appears to be a novel finding, and might explain the extreme variations in outcomes observed by others. Further studies are necessary to understand the mechanism underlying lack of sirolimus effects in significant numbers of HD patients.
